Joy Yan
Chief Tech/Sci/R&D Officer bei KEYMED BIOSCIENCES INC.
Vermögen: - $ am 31.03.2024
Aktive Positionen von Joy Yan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MOLECULIN BIOTECH, INC. | Director/Board Member | 01.03.2022 | - |
KEYMED BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 01.01.2022 | - |
Karriereverlauf von Joy Yan
Ehemalige bekannte Positionen von Joy Yan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 20.12.2021 | 31.05.2022 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | 01.10.2020 | - |
BAYER AG | Corporate Officer/Principal | - | - |
AMBRX INC | Chief Tech/Sci/R&D Officer | 01.10.2020 | - |
Ausbildung von Joy Yan
The Johns Hopkins University | Doctorate Degree |
China Medical University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
China | 3 |
Deutschland | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Doctorate Degree | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BAYER AG | Health Technology |
KEYMED BIOSCIENCES INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Moleculin Biotech, Inc. | |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |